OptiNose AS, which focuses on treating ear, nose and throat (ENT) and allergy diseases, announced that the Pennsylvania-based pharmaceutical company’s Phase III ReOpen1 clinical trial met both co-primary endpoints.

AstraZeneca Plc said the company’s asthma treatment Fasenra for a chronic inflammatory disease of the nasal passage linings, or sinuses, met main goals in a late-stage study.

GOTEBORG, Sweden — Could Meda AB be selling off its U.S. operations? Some sources are suggesting a deal could be in the works. Late Thursday, Bloomberg Business, citing “people familiar with the matter,” reported Sweden-based Meda was exploring options to sell off its U.S. operations which have an estimated value of $1 billion. Meda, which […]